Trial Profile
A Randomized, Double-blind, Placebo-controlled and Open-label, Active Controlled, 4 Period Crossover Trial to Evaluate the Effect of BIA 5 1058 on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Zamicastat (Primary) ; Moxifloxacin
- Indications Cardiovascular disorders; Heart failure; Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors BIAL - Portela C S.A.
- 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
- 31 Oct 2019 Status changed from active, no longer recruiting to completed.
- 12 Oct 2018 Planned End Date changed from 1 Sep 2018 to 5 Oct 2018.